A federal judge has ordered the Pentagon to justify why testosterone treatment is being marketed as a readiness benefit for some troops while identical hormone care is invoked to force transgender service members out of uniform. U.S. District Judge Ana Reyes issued the directive Wednesday, instructing the parties fighting and defending President Donald Trump’s transgender military ban to grapple with Defense Secretary Pete Hegseth’s newly unveiled testosterone program as the litigation heads toward trial.
The order came after Hegseth appeared before the Senate Appropriations Committee on July 21, 2026, testifying inside the Dirksen Senate Office Building on Capitol Hill in Washington, D.C. His testimony came amid mounting scrutiny of a policy critics say exposes a glaring contradiction at the heart of the administration’s arguments.
The Same Hormone, Two Standards
Reyes took judicial notice of Hegseth’s announcement from July 15, 2026, in which he said that all service members 30 and older, including women, would undergo annual screening for testosterone deficiency. Troops found to have low levels could then voluntarily begin testosterone replacement therapy, known as TRT, as part of their routine health assessments. Personnel under 30 may volunteer to be tested.
The judge then set that program directly against the language of Trump’s military ban. That policy declares service members must meet demanding mental and physical standards “without the benefit” of routine medical treatment or special provisions. Reyes stated that she must consider whether the new policy changes the legal standing of either party in Talbott v. United States, and she set an August 7 deadline for written arguments.
Administration officials have contended that service members who are transgender may be barred because their care involves continuous medical intervention. Yet Hegseth’s screening program offers continuing hormone therapy to potentially large numbers of troops, raising the question at the core of Reyes’ order: why one form of hormone care disqualifies a soldier while another is promoted as a performance benefit.
What Hegseth Announced
Hegseth rolled out the initiative in a video posted to social media, describing the screenings as necessary to allow troops to operate at their “absolute best.” Though he referred broadly to troops, the video appears to focus only on testing men in uniform for hormone irregularities. When pressed on what conditions the policy aimed to address, the Pentagon pointed to Hegseth’s remarks about keeping troops strong, resilient and capable and meeting the demands of the modern battlefield.
Hegseth said the effort was not about artificial enhancement. But the Pentagon declined to say what research or academic studies underpinned the move, and it did not address whether female troops would be evaluated for estrogen-based therapy as they entered perimenopause.
The announcement dovetails with a broader push from within the administration. Health Secretary Robert F. Kennedy Jr. and other officials have moved to make testosterone easier to prescribe. Last month, the Food and Drug Administration (FDA) proposed loosening prescribing limits on testosterone gels, pills, patches and injections. The agency’s current label restricts the drugs to men with hypogonadism, a condition causing drastically low testosterone, and the FDA eliminated a safety alert concerning cardiovascular dangers in the previous year.
Science and Scrutiny
As men grow older, their bodies produce less testosterone, a change that researchers have connected to erectile dysfunction, low libido, mood changes and weight gain. National Institutes of Health studies in older men found the hormone improved erectile function, libido and other sexual measures, but showed little or no improvement in fatigue, memory or overall well-being. Other research has pointed to potential gains in muscle-building, strength and bone density. Current medical guidelines generally advise against blanket testing of testosterone levels in the general population.
The military has its own troubled history with the hormone. Special operations forces, and Navy SEALs in particular, have faced scrutiny over the use of testosterone and similar substances to boost performance. A SEAL recruit who died during a 2022 training exercise was found with substances including testosterone, revealing that drug use within the elite unit was far more common than officials had previously disclosed. A year later, the Navy launched a drug-testing program to screen for hormonal substances related to testosterone.
Reyes ordered both sides to address six areas in the coming briefing on discovery and summary judgment. Among them, the parties must lay out the medical guidelines for routinely screening the general population for testosterone deficiency, explain the standards for monitoring patients once TRT begins, and detail recommendations for testing people who show symptoms of low testosterone.
By placing Hegseth’s screening program beside the military ban’s own words, the judge has forced the administration to reconcile two positions that critics say cannot coexist. The August 7 deadline now sets the stage for the government to explain, on the record, how the same class of hormone treatment can be both a readiness tool and a disqualifying condition.